- Home
- SNGX vs CHRO Comparison
SNGX vs CHRO Comparison
Compare SNGX & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- CHRO
- Stock Information
- Founded
- SNGX 1987
- CHRO 2002
- Country
- SNGX United States
- CHRO United States
- Employees
- SNGX N/A
- CHRO N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- CHRO
- Sector
- SNGX Health Care
- CHRO
- Exchange
- SNGX Nasdaq
- CHRO Nasdaq
- Market Cap
- SNGX 6.5M
- CHRO 7.6M
- IPO Year
- SNGX 1987
- CHRO 2024
- Fundamental
- Price
- SNGX $1.37
- CHRO $1.35
- Analyst Decision
- SNGX
- CHRO
- Analyst Count
- SNGX 0
- CHRO 0
- Target Price
- SNGX N/A
- CHRO N/A
- AVG Volume (30 Days)
- SNGX 147.3K
- CHRO 135.3K
- Earning Date
- SNGX 08-08-2025
- CHRO 08-12-2025
- Dividend Yield
- SNGX N/A
- CHRO N/A
- EPS Growth
- SNGX N/A
- CHRO N/A
- EPS
- SNGX N/A
- CHRO N/A
- Revenue
- SNGX $2,342.00
- CHRO N/A
- Revenue This Year
- SNGX N/A
- CHRO N/A
- Revenue Next Year
- SNGX N/A
- CHRO N/A
- P/E Ratio
- SNGX N/A
- CHRO N/A
- Revenue Growth
- SNGX N/A
- CHRO N/A
- 52 Week Low
- SNGX $1.31
- CHRO $0.45
- 52 Week High
- SNGX $14.83
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- SNGX 23.71
- CHRO 63.60
- Support Level
- SNGX $1.31
- CHRO $1.12
- Resistance Level
- SNGX $1.95
- CHRO $1.23
- Average True Range (ATR)
- SNGX 0.07
- CHRO 0.16
- MACD
- SNGX -0.05
- CHRO 0.01
- Stochastic Oscillator
- SNGX 9.56
- CHRO 30.26
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.